MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Treatment

Oncolytic Viral Therapy for Mesothelioma

Frontiers in Oncology 2017 August 24 [Link] Pease DF, Kratzke RA Abstract The limited effectiveness of conventional therapy for malignant pleural mesothelioma demands innovative approaches to this difficult disease. Even with aggressive multimodality treatment of surgery, radiation, and/or chemotherapy, the median survival is only 1-2 years depending on stage and histology. Oncolytic viral therapy has emerged […]

Comments Off on Oncolytic Viral Therapy for Mesothelioma

Radiotherapy for the treatment of malignant pleural mesothelioma

The Lancet. Oncology 2017 September [Link] Perrot M1, Wu L, Wu M, Cho BCJ Abstract Malignant pleural mesothelioma is an aggressive disease that continues to be associated with poor outcomes. Although, traditionally this disease is considered to be resistant to radiotherapy, more recent evidence suggests that radiotherapy can produce positive outcomes. Over the past 15 […]

Comments Off on Radiotherapy for the treatment of malignant pleural mesothelioma

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Journal of Clinical Oncology 2017 September 11 [Epub ahead of print] [Link] Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G Abstract Purpose LUME-Meso is a phase […]

Comments Off on Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity

American Journal of Cancer Research 2017 August [Link] Tan Y, Sementino E, Chernoff J, Testa JR Abstract Clinical management of malignant mesothelioma (MM) is very challenging due to marked resistance of this tumor to chemotherapy. Various mechanisms lead to a less than ideal drug concentration inside of MM cells, diminishing cytotoxicity. Consequently, single cytotoxic drugs […]

Comments Off on Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity

Near-Infrared Intraoperative Imaging Can Successfully Identify Malignant Pleural Mesothelioma After Neoadjuvant Chemotherapy

Molecular Imaging 2017 January-December [Link] Predina JD, Newton A, Kennedy G, Lee MK, Singhal S Abstract Malignant pleural mesothelioma is a deadly disease. Complete surgical resection provides patients with the best opportunity for long-term survival. Unfortunately, identification of disease during resection can be challenging. In this report, we describe successful intraoperative utilization of the near-infrared […]

Comments Off on Near-Infrared Intraoperative Imaging Can Successfully Identify Malignant Pleural Mesothelioma After Neoadjuvant Chemotherapy

The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review

Radiotherapy and Oncology 2017 August [Epub ahead of print] [Link] Ashton M1, O’Rourke N2, Currie S2, Rimner A3, Chalmers A Abstract Malignant pleural mesothelioma (MPM) is a devastating disease with limited treatment options and a dismal prognosis. Attempts to employ radical radiotherapy in this disease have been limited by the complex shape of the pleura […]

Comments Off on The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

Cancers 2017 September [Link] Klampatsa A, Haas AR, Moon EK, Albelda SM Abstract Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs […]

Comments Off on Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

Malignant pleural mesothelioma – Pleural cavity irradiation after decortication with helical tomotherapy

Reports of Practical Oncology and Radiotherapy 2017 September [Epub 2017 August 11] [Link] Harrabi SB, Koerber SA, Adeberg S, Katayama S, Herfarth K, Debus J, Sterzing F Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive disease that poses a treatment challenge in spite of recent technical developments. The aim of this retrospective […]

Comments Off on Malignant pleural mesothelioma – Pleural cavity irradiation after decortication with helical tomotherapy

Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes

Lung Cancer 2017 September [Epub 2017 July 13] [Link] Lau B, Kumar S, Yan T, Burn J, Kennedy C, McLean J, Boyer M, McCaughan B, Kao S Abstract A small proportion of patients with malignant pleural mesothelioma (MPM) achieve pathological complete response (CR) following treatment with current practice induction chemotherapy. Our analysis of 58 patients […]

Comments Off on Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes

Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response

Asian Pacific Journal of Cancer Prevention 2017 August [Link] Rahouma M, Aziz H, Ghaly G, Kamel M, Loai I, Mohamed A Abstract Purpose: Malignant pleural mesothelioma (MPM) has a poor prognosis in general. Here we sought to evaluate prognostic factors and predictors of response to chemotherapy in good performance (PS=0-I) patients. Methods: We retrospectively reviewed […]

Comments Off on Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response